as aggressive fibromatosis), after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400 mg vs 800 mg). NCI are sponsoring this trial. Notes References External links Bayer brands Orphan drugs Receptor tyrosine kinase inhibitors Chloroarenes Trifluoromethyl compounds Anilines Ureas Phenol ethers Pyridines Carboxamides Diaryl ethers